BiMVaC01 - RCT to compare the bivalent Omicron BA.4/BA.5 and Comirnaty COVID-19 vaccine formulations
Starting on:
May 4, 2023
Ending on:
May 4, 2023
Moderator(s):
Venue:
KWTR Kilifi Campus/Online
Max Credits:
3 Points

Provider:
KEMRI-WELLCOME TRUST RESEARCH PROGRAMME
Claim Points

BiMVaC01 - RCT to compare the bivalent Omicron BA.4/BA.5 and Comirnaty COVID-19 vaccine formulations

Starting on:
May 4, 2023
Ending on:
May 4, 2023
Venue:
KWTR Kilifi Campus/Online

Description

Regular scientific seminar

Objectives

A randomised, controlled clinical trial to assess and compare the immunogenicity, safety and reactogenicity of the bivalent Omicron BA.4/BA.5 adapted, and Comirnaty (Original Pfizer), COVID-19 vaccine formulations in healthy unvaccinated East African adults

Presenters

  1. Prof. Fancis Ndung'u
    I am a malaria immunologist interested in understanding how semi-immune individuals control malaria parasite growth and the associated inflammation (symptoms) – and the potential translation of that knowledge in the development of effective malaria vaccines.
    KWTRP

  2. Dr. Kimani Makobu
    Makobu Kimani is a medical doctor, with post graduate training in public Health (Epidemiology and Biostatistics). Over the last eight years he has worked with populations that are at a disproportionally higher risk of acquisition of HIV/AIDS in Nairobi, Kenya. Kimani has also been a clinical safety advisor for an RCT inducing immune-quiescence in female sex workers. He has been part of a team that defined the minimal care package for services to female sex workers and MSM/MSW. This is currently being implemented by the Ministry of health in Kenya. He is interested in mental health and its attendant contribution to risk taking behaviour in MSM that exposes them to even higher risk for HIV acquisition. He has also developed an interest for finding Acute HIV Infection (AHI) in the general population and its potential for use for both behavioural studies and HIV vaccine trials.
    KWTRP

Search For CPD Activity